查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2015173

非侵入性產前檢測市場：依檢測類型、技術、懷孕週數、交付方式及最終用戶分類－2026年至2032年全球市場預測

Non-invasive Prenatal Testing Market by Test Type, By Technology, Gestation Period, Mode of Delivery, End-User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，非侵入性產前檢測市場價值將達到 69.3 億美元，到 2026 年將成長至 73.6 億美元，到 2032 年將達到 119.5 億美元，年複合成長率為 8.10%。

主要市場統計數據
基準年 2025 69.3億美元
預計年份：2026年 73.6億美元
預測年份 2032 119.5億美元
複合年成長率 (%) 8.10%

本書將臨床進展、患者期望以及影響產前診斷的操作挑戰交織在一起，描繪了整體情況。

受定序和生物資訊學進步以及以患者為中心的醫療保健體系的推動，非侵入性產前檢測已從一種小眾篩檢手段發展成為產前護理的核心支柱。目前，臨床醫生依靠cfDNA分析來確定早期懷孕診斷方案，而準媽媽及其伴侶則希望獲得更清晰的諮詢和更少的侵入性選擇。因此，醫學界和商業相關人員正在探索一個快速變化的領域，在這個領域中，技術能力、監管和保險公司的接受度都面臨著挑戰​​。

技術快速成熟、檢體採集分散化以及不斷變化的監管預期，正在從根本上重新定義產前診斷服務的提供方式。

近年來，在技術融合和醫療服務模式轉變的推動下，非侵入性產前檢測（NIPT）經歷了變革性的變化。次世代定序平台和更先進的生物資訊演算法拓展了檢測範圍，使其不再局限於常見的染色體三體，而是能夠高解析度地識別更廣泛的染色體異常和微缺失。同時，檢測設計和檢查室自動化的進步縮短了檢測時間，並提高了結果的可重複性。這反過來又加快了臨床決策速度，並簡化了產前診斷在日常工作流程中的整合。

評估新的進口關稅對產前診斷的成本結構和策略採購決策的影響，以及這些影響對營運、供應鏈和支付方的影響。

2025年起對部分進口檢測設備、耗材和試劑徵收關稅，為無創產前檢測的經濟效益帶來了新的變數。對於依賴全球供應鏈採購定序儀、試劑和精密光學儀器的檢測實驗室和設備製造商而言，關稅帶來的成本調整正在擠壓其營業利潤率，迫使其重新評估籌資策略。許多機構正在透過審查庫存管理方法、與供應商談判長期合約以及加快討論供應鏈韌性和近岸外包等方式來應對這一挑戰。

透過對測試類型、技術平台、懷孕階段、分娩模式和臨床最終用戶進行詳細的細分分析，揭示了策略機會領域。

市場區隔洞察清楚地展現了臨床需求、技術能力和服務產品之間的交集，從而形成差異化的價值提案。根據檢測類型，市場涵蓋染色體數目異常篩檢，包括三體症候群，例如13號染色體三體症候群（巴陶氏症）、18號染色體三體症候群（愛德華氏症候群）和21號染色體三體症候群（唐氏症） ；微缺失症候群，涵蓋1p36缺失、22q11.2缺失（迪喬治症候群）和貓叫症候群等疾病；性染色體非整倍體，包括柯林菲特氏症症候群（XXY）、三X透納氏症（X染色體單染性）和XYY症候群；以及用於擴大檢測範圍的全基因組篩檢方法。每種檢測類型在分析靈敏度、諮詢複雜性和確認性檢測流程方面都有其獨特的要求，這些要求會影響檢查室的配置和臨床應用。

美洲、歐洲、中東和非洲以及亞太地區在區域實施模式和政策上的細微差異，決定了不同的市場進入和服務模式。

區域趨勢持續影響非侵入性產前檢測的普及模式、監管預期和商業策略。在美洲，成熟的報銷機制、產科服務提供者較高的臨床應用率以及充滿活力的商業檢測實驗室格局，促使企業更加關注臨床效用研究、與保險公司的合作以及服務差異化。該地區的新參與企業通常優先考慮與醫療系統建立合作關係，並投資提升檢測能力，以滿足臨床需求，同時關注服務不足社區的公平獲取途徑。

垂直整合、檢驗主導差異化、策略聯盟和選擇性併購等因素驅動的競爭動態正在塑造產前診斷領域的企業策略。

非侵入性產前檢測領域的企業競爭呈現出垂直整合、平台差異化和策略聯盟並存的局面。領先的診斷公司和臨床實驗室正加大對檢測方法檢驗、先進生物資訊學和拓展適應症的投資，以強化其實證醫學定位。同時，儀器製造商、試劑供應商和臨床服務供應商之間的合作也日益普遍，這主要是由於需要整合解決方案以降低醫院系統和大規模實驗室網路採用新技術的門檻。

領導企業應採取切實可行的策略重點，同時加強臨床有效性、供應鏈韌性、支付方合作以及以患者為中心的服務模式。

產業領導企業必須採取多管齊下的策略，才能在獲得商業性利益的同時，保持臨床信譽。首先，投資於嚴謹的臨床檢驗研究和真實世界數據（REW）項目，有助於提升企業在保險公司和臨床醫生中的地位，並促進指南的更廣泛應用。其次，供應鏈多元化和加強與供應商的關係，可以降低進口關稅和零件短缺帶來的風險。此外，企業也應盡可能考慮近岸外包和多供應商策略，以維持業務永續營運。

我們嚴謹且多方面的調查方法，結合專家訪談、臨床文獻整合和迭代檢驗，為可靠的市場洞察和建議提供了支持。

本研究途徑結合了對關鍵相關人員的訪談、對二手文獻的整合以及調查方法的三角驗證，以得出平衡且令人信服的結論。主要研究包括與臨床遺傳學家、實驗室主任、產科負責人和企業高管進行結構化對話，以了解當前的實踐模式、採購重點和創新藍圖。此外，還對同行評審的臨床研究、監管指南和已發表的技術概述進行了系統性回顧，以檢驗分析表現的屬性和臨床效用說明的準確性。

概述如何協調技術進步、政策演變和營運韌性，以最大限度地發揮產前篩檢的臨床和商業性潛力。

總而言之，非侵入性產前檢測生態系統正處於一個轉折點，隨著技術進步、檢測方法創新和政策轉變的交匯，臨床實踐和商業模式正在重塑。分析能力的提升和檢體採集方法的改進擴大了檢測的可及性和臨床效用，而不斷變化的支付方和法律規範則提高了廣泛應用所需的證據門檻。這些並行的趨勢為致力於提供高品質產前服務的製造商、檢測實驗室和醫療保健系統帶來了機會和挑戰。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 按檢測類型分類的非侵入性產前檢測市場

  • 非整倍體篩檢
    • 13號染色體三體症候群（巴陶氏症）
    • 18號染色體三體綜合症（愛德華氏症候群）
    • 21三體症（唐氏症）
  • 微缺失症候群
    • 1p36 缺失
    • 22q11.2缺失（迪喬治症候群）
    • 尖叫症候群
  • 性染色體非整倍體（SCA）
    • 柯林菲特氏症（XXY）
    • 三X症候群（XXX）
    • 透納氏症（X染色體單染色單體症候群）
    • XYY綜合症
  • 全基因組篩檢

第9章 依技術分類的非侵入性產前檢測市場

  • 利用微陣列進行分析
  • 次世代定序（NGS）
  • 聚合酵素鏈鎖反應（PCR）
  • 滾動循環放大器（RCA）

第10章 依孕週分類的非侵入性產前檢測市場

  • 10-17週
  • 18-23週
  • 23週或以上

第11章 以交付方式分類的非侵入性產前檢測市場

  • 家庭檢體收集
  • 檢測實驗室提供的檢測服務
  • 即時檢測

第12章 非侵入性產前檢測市場：依最終用戶分類

  • 診斷檢查室
  • 醫院
  • 專科診所

第13章 非侵入性產前檢測市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 非侵入性產前檢測市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 非侵入性產前檢測市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國無創產前檢測市場

第17章：中國無創產前檢測市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Agilent Technologies, Inc.
  • BGI Group
  • BillionToOne, Inc.
  • Biora Therapeutics, Inc.
  • BioReference Laboratories, Inc.
  • Centogene NV
  • Eurofins Scientific SE
  • F.Hoffmann-La Roche Ltd.
  • GE HealthCare Technologies Inc.
  • Igenomix SLU by Vitrolife Group
  • Illumina, Inc.
  • Labcorp Holdings Inc.
  • Laboratory Corporation of America Holdings
  • Lilac Insights Pvt. Ltd.
  • MedGenome Labs Ltd.
  • Myriad Genetics, Inc.
  • Natera, Inc.
  • Quest Diagnostics Incorporated
  • Ravgen Inc.
  • Sonic Healthcare USA
  • Thermo Fisher Scientific Inc.
  • Yourgene Health by Novacyt UK Holdings Limited
Product Code: MRR-036C5CF3B521

The Non-invasive Prenatal Testing Market was valued at USD 6.93 billion in 2025 and is projected to grow to USD 7.36 billion in 2026, with a CAGR of 8.10%, reaching USD 11.95 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 6.93 billion
Estimated Year [2026] USD 7.36 billion
Forecast Year [2032] USD 11.95 billion
CAGR (%) 8.10%

Framing the modern non-invasive prenatal testing landscape by weaving together clinical advances, patient expectations, and operational challenges shaping prenatal diagnostics

Non-invasive prenatal testing has evolved from a niche screening adjunct to a central pillar of prenatal care, shaped by advances in sequencing, bioinformatics, and an increasingly patient-centric health ecosystem. Clinicians now rely on cell-free DNA analysis to inform diagnostic pathways earlier in pregnancy, while expectant parents expect clearer counseling and less invasive options. As a result, the clinical community and commercial stakeholders are navigating a rapidly changing interface where technological capability, regulatory oversight, and payer acceptance intersect.

Consequently, the landscape demands rigorous evidence generation and thoughtful integration of laboratory workflows with obstetric care. Laboratories are balancing precision and throughput, hospitals are recalibrating protocols for prenatal counseling, and specialty clinics are refining patient engagement models to reflect both clinical utility and ethical considerations. Moreover, as diagnostic sophistication increases, so does the responsibility to ensure equitable access, clarity of results, and robust post-test follow-up. This introduction frames the broader market forces and clinical imperatives that underpin the subsequent analysis and recommendations.

How rapid technological maturation, decentralization of sample collection, and evolving regulatory expectations are fundamentally redefining prenatal diagnostic care delivery

The last several years have seen transformative shifts in non-invasive prenatal testing driven by technological convergence and shifting care delivery models. Next-generation sequencing platforms and more sophisticated bioinformatic algorithms have expanded detection capabilities beyond common trisomies, enabling identification of a broader range of chromosomal abnormalities and microdeletions with increasing resolution. At the same time, improvements in assay design and laboratory automation have compressed turnaround times and improved reproducibility, allowing for faster clinical decision-making and more streamlined integration into prenatal workflows.

Simultaneously, the market is experiencing a movement toward decentralization of sample collection and patient engagement. At-home sample kits and point-of-care testing modalities are gaining traction, creating opportunities for earlier access and greater convenience, while also raising new questions around quality control, patient education, and data security. Alongside these delivery changes, regulatory bodies and payers are progressively refining coverage frameworks and evidence requirements. This regulatory maturation, together with expanded clinical validation studies, is encouraging broader clinical adoption but also raising the bar for manufacturers and laboratories in terms of clinical utility and cost-effectiveness. Taken together, these shifts are not merely incremental; they are redefining how prenatal screening is offered, interpreted, and acted upon across multiple points of care.

Evaluating the operational, supply chain, and payer-level consequences of new import tariffs that are reshaping cost structures and strategic sourcing decisions in prenatal diagnostics

The introduction of tariffs on certain imported laboratory equipment, consumables, and reagents in 2025 has introduced a new variable into the economics of non-invasive prenatal testing. For laboratories and device manufacturers that depend on global supply chains for sequencers, reagents, and precision optics, tariff-driven cost adjustments have translated into tighter operating margins and renewed scrutiny of procurement strategies. In many places, organizations have responded by revising inventory management practices, negotiating longer-term supplier contracts, and accelerating conversations around supply chain resilience and nearshoring.

Beyond immediate cost pressures, tariffs have catalyzed strategic thinking around localization of manufacturing and diversification of component sourcing. Companies with vertically integrated operations or those able to substitute domestically produced inputs have gained relative operational flexibility. In addition, the tariff environment has prompted greater collaboration between manufacturers and payers to reassess reimbursement constructs, as stakeholders align on how to preserve patient access without compromising clinical quality. Finally, the policy environment underscores the importance of transparent cost communication and proactive regulatory engagement to mitigate downstream effects on testing availability, laboratory consolidation, and innovation trajectories.

Granular segmentation analysis linking assay types, technology platforms, gestational timing, delivery models, and clinical end-users to reveal strategic opportunity zones

Insight into market segmentation clarifies where clinical need, technological capability, and service delivery intersect to create differentiated value propositions. Based on test type, the market is organized around aneuploidy screening that includes trisomies such as Trisomy 13 (Patau Syndrome), Trisomy 18 (Edwards Syndrome), and Trisomy 21 (Down Syndrome), microdeletion syndromes that cover conditions like 1p36 Deletion, 22q11.2 Deletion (DiGeorge Syndrome), and Cri-du-chat Syndrome, sex chromosome aneuploidies encompassing Klinefelter Syndrome (XXY), Triple X Syndrome (XXX), Turner Syndrome (Monosomy X), and XYY Syndrome, as well as whole-genome screening approaches that expand the detection envelope. Each test type imposes distinct requirements for analytical sensitivity, counseling complexity, and confirmatory workflows, which in turn influence laboratory architecture and clinical adoption.

From a technology standpoint, the competitive dynamics revolve around microarray-based analysis, next-generation sequencing, polymerase chain reaction techniques, and rolling circle amplification methods. Technologies differ not only in analytical throughput and cost per sample but also in bioinformatic complexity and validation expectations, thereby guiding purchasing priorities and partnership strategies. Considering gestation period, segmentation across 10-17 weeks, 18-23 weeks, and above 23 weeks shapes clinical utility, since earlier testing enables different counseling and management options compared with later gestational windows. Mode of delivery segmentation across at-home sample collection, laboratory-based testing services, and point-of-care testing highlights divergent operational models and patient experience trade-offs. Finally, end-user segmentation that includes diagnostic laboratories, hospitals, and specialty clinics captures how testing volumes, clinical pathways, and service level expectations vary, thereby affecting sales channels, payer interactions, and clinical education strategies. Integrated analysis across these segments reveals where innovation and commercial focus can yield the greatest clinical and economic impact.

Regional adoption patterns and policy nuances across the Americas, Europe Middle East & Africa, and Asia-Pacific that dictate differentiated market entry and service models

Regional dynamics continue to shape adoption patterns, regulatory expectations, and commercial strategies in non-invasive prenatal testing. In the Americas, mature reimbursement frameworks, high clinical adoption among obstetric providers, and a dynamic landscape of commercial laboratories drive a focus on clinical utility studies, payer engagement, and service differentiation. Market participants in this region often prioritize partnerships with healthcare systems and investments in rapid laboratory throughput to meet clinical demand while simultaneously addressing concerns around equitable access in underserved communities.

Conversely, Europe, Middle East & Africa presents a heterogeneous environment where regulatory regimes and payer models vary significantly by country, prompting tailored evidence generation and market entry approaches. In several European markets, centralized public healthcare systems emphasize cost-effectiveness and national guideline alignment, while in parts of the Middle East and Africa, infrastructure and access constraints necessitate strategies centered on capacity-building and clinician education. Meanwhile, Asia-Pacific reflects a mixture of rapid adoption in urban centers, growing private lab networks, and increasing investments in local manufacturing and genomics capabilities. In this region, early-mover providers are prioritizing localization of services, multilingual patient engagement, and collaborations with regional health authorities to scale access. Across all regions, cross-border collaborations, data privacy considerations, and the need for culturally appropriate counseling remain recurrent themes that companies must navigate thoughtfully.

Competitive dynamics driven by vertical integration, validation-led differentiation, strategic partnerships, and selective consolidation shaping corporate strategies in prenatal diagnostics

Competitive behavior among companies active in non-invasive prenatal testing is characterized by a mix of vertical integration, platform differentiation, and strategic partnerships. Leading diagnostics firms and clinical laboratories are investing in assay validation, bioinformatics refinement, and expanded clinical indications to strengthen evidentiary positioning. At the same time, collaborations between instrument manufacturers, reagent suppliers, and clinical service providers are becoming more common as organizations seek to bundle solutions that reduce implementation friction for hospital systems and large laboratory networks.

In parallel, smaller innovators are carving niche positions by focusing on at-home collection platforms, enhanced patient reporting interfaces, or specialized microdeletion panels. Consolidation activity is evident as market participants pursue acquisitions to secure intellectual property, expand geographic footprints, or accelerate entry into adjacent testing modalities. Importantly, regulatory compliance and third-party accreditation remain differentiators; companies that demonstrate rigorous clinical validation, transparent performance characteristics, and robust quality systems typically gain preferential consideration from institutional purchasers and payers. Overall, the competitive landscape rewards those that combine scientific rigor with scalable operations and a clear pathway to reimbursement.

Practical strategic priorities for diagnostic leaders to strengthen clinical validation, supply resilience, payer engagement, and patient-centric delivery models concurrently

Industry leaders must adopt a multi-pronged set of actions to sustain clinical credibility while capturing commercial upside. First, investing in rigorous clinical validation studies and real-world evidence programs will strengthen positioning with payers and clinicians and will facilitate broader guideline adoption. Second, diversifying supply chains and building stronger vendor relationships will mitigate exposure to import tariffs and component shortages, and firms should evaluate nearshoring or multi-supplier strategies where feasible to preserve operational continuity.

Third, organizations should prioritize patient-centric delivery models that improve access and comprehension, including expansion of at-home collection programs coupled with clinician-mediated counseling pathways. Fourth, strengthening payer engagement through evidence-based value dossiers and outcomes data will be critical to securing sustainable reimbursement. Concurrently, companies should pursue scalable automation in laboratories and invest in interoperable data systems to reduce turnaround times and lower per-test operational costs. Finally, consider strategic partnerships or targeted M&A to obtain missing capabilities-whether in bioinformatics, sample collection, or regional market access-thereby accelerating time to market and minimizing execution risk. These recommendations create an operational playbook that balances clinical rigor with commercial pragmatism.

A rigorous, multi-source research methodology combining expert interviews, clinical literature synthesis, and iterative validation to underpin credible market insights and recommendations

The research approach integrates primary stakeholder interviews, secondary literature synthesis, and methodological triangulation to ensure balanced, defensible conclusions. Primary research involved structured conversations with clinical geneticists, laboratory directors, obstetric leaders, and commercial executives to capture contemporary practice patterns, procurement priorities, and innovation roadmaps. These insights were complemented by a systematic review of peer-reviewed clinical studies, regulatory guidance, and published technical briefs to validate analytical performance attributes and clinical utility narratives.

Data were cross-checked through iterative validation sessions with subject-matter experts to refine assumptions about laboratory workflows, technology adoption hurdles, and regional policy implications. Qualitative findings were further contextualized with vendor product literature and operational case studies to highlight practical implementation considerations. Finally, methodological safeguards included transparency around inclusion criteria, a clear audit trail for expert inputs, and sensitivity checks on interpretative conclusions to ensure that recommendations remain robust across plausible market scenarios.

Concluding synthesis of how technological advances, policy evolution, and operational resilience must be aligned to realize the full clinical and commercial potential of prenatal screening

In summary, the non-invasive prenatal testing ecosystem stands at an inflection point where technological advances, delivery innovations, and policy shifts converge to reshape clinical practice and commercial models. Enhanced analytical capabilities and novel modes of sample collection are expanding access and clinical utility, while evolving payer and regulatory frameworks are raising the evidence threshold for broad adoption. These parallel developments create both opportunity and complexity for manufacturers, laboratories, and health systems seeking to deliver high-quality prenatal care.

As stakeholders respond to operational pressures such as tariff-induced cost adjustments and supply chain vulnerabilities, those who invest in evidence generation, supply resilience, and patient-centered delivery will be better positioned to lead. The path forward requires coordinated action across clinical, commercial, and policy fronts to ensure that advances in non-invasive prenatal testing translate into meaningful improvements in prenatal care, equitable access, and informed decision-making for families.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Non-invasive Prenatal Testing Market, by Test Type

  • 8.1. Aneuploidy Screening
    • 8.1.1. Trisomy 13 (Patau Syndrome)
    • 8.1.2. Trisomy 18 (Edwards Syndrome)
    • 8.1.3. Trisomy 21 (Down Syndrome)
  • 8.2. Microdeletion Syndromes
    • 8.2.1. 1p36 Deletion
    • 8.2.2. 22q11.2 Deletion (DiGeorge Syndrome)
    • 8.2.3. Cri-du-chat Syndrome
  • 8.3. Sex Chromosome Aneuploidies (SCA)
    • 8.3.1. Klinefelter Syndrome (XXY)
    • 8.3.2. Triple X Syndrome (XXX)
    • 8.3.3. Turner Syndrome (Monosomy X)
    • 8.3.4. XYY Syndrome
  • 8.4. Whole-Genome Screening

9. Non-invasive Prenatal Testing Market, by By Technology

  • 9.1. Microarray-Based Analysis
  • 9.2. Next-Generation Sequencing (NGS)
  • 9.3. Polymerase Chain Reaction (PCR)
  • 9.4. Rolling Circle Amplification (RCA)

10. Non-invasive Prenatal Testing Market, by Gestation Period

  • 10.1. 10-17 Week
  • 10.2. 18-23 Week
  • 10.3. Above 23 Week

11. Non-invasive Prenatal Testing Market, by Mode of Delivery

  • 11.1. At-Home Sample Collection
  • 11.2. Laboratory-Based Testing Services
  • 11.3. Point-of-Care Testing

12. Non-invasive Prenatal Testing Market, by End-User

  • 12.1. Diagnostic Laboratories
  • 12.2. Hospitals
  • 12.3. Specialty Clinics

13. Non-invasive Prenatal Testing Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Non-invasive Prenatal Testing Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Non-invasive Prenatal Testing Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Non-invasive Prenatal Testing Market

17. China Non-invasive Prenatal Testing Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Agilent Technologies, Inc.
  • 18.6. BGI Group
  • 18.7. BillionToOne, Inc.
  • 18.8. Biora Therapeutics, Inc.
  • 18.9. BioReference Laboratories, Inc.
  • 18.10. Centogene N.V.
  • 18.11. Eurofins Scientific SE
  • 18.12. F.Hoffmann-La Roche Ltd.
  • 18.13. GE HealthCare Technologies Inc.
  • 18.14. Igenomix S.L.U by Vitrolife Group
  • 18.15. Illumina, Inc.
  • 18.16. Labcorp Holdings Inc.
  • 18.17. Laboratory Corporation of America Holdings
  • 18.18. Lilac Insights Pvt. Ltd.
  • 18.19. MedGenome Labs Ltd.
  • 18.20. Myriad Genetics, Inc.
  • 18.21. Natera, Inc.
  • 18.22. Quest Diagnostics Incorporated
  • 18.23. Ravgen Inc.
  • 18.24. Sonic Healthcare USA
  • 18.25. Thermo Fisher Scientific Inc.
  • 18.26. Yourgene Health by Novacyt UK Holdings Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY GESTATION PERIOD, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MODE OF DELIVERY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES NON-INVASIVE PRENATAL TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA NON-INVASIVE PRENATAL TESTING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY ANEUPLOIDY SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY ANEUPLOIDY SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY ANEUPLOIDY SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY ANEUPLOIDY SCREENING, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TRISOMY 13 (PATAU SYNDROME), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TRISOMY 13 (PATAU SYNDROME), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TRISOMY 13 (PATAU SYNDROME), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TRISOMY 18 (EDWARDS SYNDROME), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TRISOMY 18 (EDWARDS SYNDROME), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TRISOMY 18 (EDWARDS SYNDROME), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TRISOMY 21 (DOWN SYNDROME), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TRISOMY 21 (DOWN SYNDROME), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TRISOMY 21 (DOWN SYNDROME), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MICRODELETION SYNDROMES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MICRODELETION SYNDROMES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MICRODELETION SYNDROMES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MICRODELETION SYNDROMES, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY 1P36 DELETION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY 1P36 DELETION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY 1P36 DELETION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY 22Q11.2 DELETION (DIGEORGE SYNDROME), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY 22Q11.2 DELETION (DIGEORGE SYNDROME), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY 22Q11.2 DELETION (DIGEORGE SYNDROME), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY CRI-DU-CHAT SYNDROME, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY CRI-DU-CHAT SYNDROME, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY CRI-DU-CHAT SYNDROME, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY SEX CHROMOSOME ANEUPLOIDIES (SCA), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY SEX CHROMOSOME ANEUPLOIDIES (SCA), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY SEX CHROMOSOME ANEUPLOIDIES (SCA), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY SEX CHROMOSOME ANEUPLOIDIES (SCA), 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY KLINEFELTER SYNDROME (XXY), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY KLINEFELTER SYNDROME (XXY), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY KLINEFELTER SYNDROME (XXY), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TRIPLE X SYNDROME (XXX), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TRIPLE X SYNDROME (XXX), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TRIPLE X SYNDROME (XXX), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TURNER SYNDROME (MONOSOMY X), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TURNER SYNDROME (MONOSOMY X), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TURNER SYNDROME (MONOSOMY X), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY XYY SYNDROME, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY XYY SYNDROME, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY XYY SYNDROME, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY WHOLE-GENOME SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY WHOLE-GENOME SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY WHOLE-GENOME SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MICROARRAY-BASED ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MICROARRAY-BASED ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MICROARRAY-BASED ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY ROLLING CIRCLE AMPLIFICATION (RCA), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY ROLLING CIRCLE AMPLIFICATION (RCA), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY ROLLING CIRCLE AMPLIFICATION (RCA), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY GESTATION PERIOD, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY 10-17 WEEK, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY 10-17 WEEK, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY 10-17 WEEK, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY 18-23 WEEK, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY 18-23 WEEK, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY 18-23 WEEK, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY ABOVE 23 WEEK, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY ABOVE 23 WEEK, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY ABOVE 23 WEEK, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MODE OF DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY AT-HOME SAMPLE COLLECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY AT-HOME SAMPLE COLLECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY AT-HOME SAMPLE COLLECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY LABORATORY-BASED TESTING SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY LABORATORY-BASED TESTING SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY LABORATORY-BASED TESTING SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY POINT-OF-CARE TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY POINT-OF-CARE TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY POINT-OF-CARE TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY ANEUPLOIDY SCREENING, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MICRODELETION SYNDROMES, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY SEX CHROMOSOME ANEUPLOIDIES (SCA), 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY GESTATION PERIOD, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MODE OF DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY ANEUPLOIDY SCREENING, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MICRODELETION SYNDROMES, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY SEX CHROMOSOME ANEUPLOIDIES (SCA), 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY GESTATION PERIOD, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MODE OF DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY ANEUPLOIDY SCREENING, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MICRODELETION SYNDROMES, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY SEX CHROMOSOME ANEUPLOIDIES (SCA), 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY GESTATION PERIOD, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MODE OF DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY ANEUPLOIDY SCREENING, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MICRODELETION SYNDROMES, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY SEX CHROMOSOME ANEUPLOIDIES (SCA), 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY GESTATION PERIOD, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MODE OF DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY ANEUPLOIDY SCREENING, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MICRODELETION SYNDROMES, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY SEX CHROMOSOME ANEUPLOIDIES (SCA), 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY GESTATION PERIOD, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MODE OF DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY ANEUPLOIDY SCREENING, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MICRODELETION SYNDROMES, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY SEX CHROMOSOME ANEUPLOIDIES (SCA), 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY GESTATION PERIOD, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MODE OF DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY ANEUPLOIDY SCREENING, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MICRODELETION SYNDROMES, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY SEX CHROMOSOME ANEUPLOIDIES (SCA), 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY GESTATION PERIOD, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MODE OF DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY ANEUPLOIDY SCREENING, 2018-2032 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MICRODELETION SYNDROMES, 2018-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY SEX CHROMOSOME ANEUPLOIDIES (SCA), 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY GESTATION PERIOD, 2018-2032 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MODE OF DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 165. ASEAN NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. ASEAN NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY ANEUPLOIDY SCREENING, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MICRODELETION SYNDROMES, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY SEX CHROMOSOME ANEUPLOIDIES (SCA), 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY GESTATION PERIOD, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MODE OF DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 173. ASEAN NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 174. GCC NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. GCC NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. GCC NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY ANEUPLOIDY SCREENING, 2018-2032 (USD MILLION)
  • TABLE 177. GCC NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MICRODELETION SYNDROMES, 2018-2032 (USD MILLION)
  • TABLE 178. GCC NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY SEX CHROMOSOME ANEUPLOIDIES (SCA), 2018-2032 (USD MILLION)
  • TABLE 179. GCC NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 180. GCC NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY GESTATION PERIOD, 2018-2032 (USD MILLION)
  • TABLE 181. GCC NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MODE OF DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 182. GCC NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPEAN UNION NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPEAN UNION NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPEAN UNION NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY ANEUPLOIDY SCREENING, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPEAN UNION NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MICRODELETION SYNDROMES, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPEAN UNION NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY SEX CHROMOSOME ANEUPLOIDIES (SCA), 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPEAN UNION NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY GESTATION PERIOD, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPEAN UNION NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MODE OF DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 192. BRICS NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. BRICS NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. BRICS NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY ANEUPLOIDY SCREENING, 2018-2032 (USD MILLION)
  • TABLE 195. BRICS NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MICRODELETION SYNDROMES, 2018-2032 (USD MILLION)
  • TABLE 196. BRICS NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY SEX CHROMOSOME ANEUPLOIDIES (SCA), 2018-2032 (USD MILLION)
  • TABLE 197. BRICS NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 198. BRICS NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY GESTATION PERIOD, 2018-2032 (USD MILLION)
  • TABLE 199. BRICS NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MODE OF DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 200. BRICS NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 201. G7 NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. G7 NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. G7 NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY ANEUPLOIDY SCREENING, 2018-2032 (USD MILLION)
  • TABLE 204. G7 NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MICRODELETION SYNDROMES, 2018-2032 (USD MILLION)
  • TABLE 205. G7 NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY SEX CHROMOSOME ANEUPLOIDIES (SCA), 2018-2032 (USD MILLION)
  • TABLE 206. G7 NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 207. G7 NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY GESTATION PERIOD, 2018-2032 (USD MILLION)
  • TABLE 208. G7 NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MODE OF DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 209. G7 NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 210. NATO NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. NATO NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. NATO NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY ANEUPLOIDY SCREENING, 2018-2032 (USD MILLION)
  • TABLE 213. NATO NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MICRODELETION SYNDROMES, 2018-2032 (USD MILLION)
  • TABLE 214. NATO NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY SEX CHROMOSOME ANEUPLOIDIES (SCA), 2018-2032 (USD MILLION)
  • TABLE 215. NATO NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 216. NATO NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY GESTATION PERIOD, 2018-2032 (USD MILLION)
  • TABLE 217. NATO NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MODE OF DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 218. NATO NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 219. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 220. UNITED STATES NON-INVASIVE PRENATAL TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 221. UNITED STATES NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. UNITED STATES NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY ANEUPLOIDY SCREENING, 2018-2032 (USD MILLION)
  • TABLE 223. UNITED STATES NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MICRODELETION SYNDROMES, 2018-2032 (USD MILLION)
  • TABLE 224. UNITED STATES NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY SEX CHROMOSOME ANEUPLOIDIES (SCA), 2018-2032 (USD MILLION)
  • TABLE 225. UNITED STATES NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 226. UNITED STATES NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY GESTATION PERIOD, 2018-2032 (USD MILLION)
  • TABLE 227. UNITED STATES NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MODE OF DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 228. UNITED STATES NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 229. CHINA NON-INVASIVE PRENATAL TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 230. CHINA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. CHINA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY ANEUPLOIDY SCREENING, 2018-2032 (USD MILLION)
  • TABLE 232. CHINA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MICRODELETION SYNDROMES, 2018-2032 (USD MILLION)
  • TABLE 233. CHINA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY SEX CHROMOSOME ANEUPLOIDIES (SCA), 2018-2032 (USD MILLION)
  • TABLE 234. CHINA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 235. CHINA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY GESTATION PERIOD, 2018-2032 (USD MILLION)
  • TABLE 236. CHINA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MODE OF DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 237. CHINA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)